Advertisement
Singapore markets open in 45 minutes
  • Straits Times Index

    3,314.05
    +0.57 (+0.02%)
     
  • S&P 500

    5,308.13
    +4.86 (+0.09%)
     
  • Dow

    39,806.77
    -196.82 (-0.49%)
     
  • Nasdaq

    16,794.88
    +108.91 (+0.65%)
     
  • Bitcoin USD

    71,121.25
    +4,919.05 (+7.43%)
     
  • CMC Crypto 200

    1,516.90
    +162.49 (+12.01%)
     
  • FTSE 100

    8,424.20
    +3.94 (+0.05%)
     
  • Gold

    2,430.60
    -7.90 (-0.32%)
     
  • Crude Oil

    79.65
    -0.15 (-0.19%)
     
  • 10-Yr Bond

    4.4370
    +0.0170 (+0.38%)
     
  • Nikkei

    39,069.68
    0.00 (0.00%)
     
  • Hang Seng

    19,636.22
    +82.61 (+0.42%)
     
  • FTSE Bursa Malaysia

    1,627.50
    +10.88 (+0.67%)
     
  • Jakarta Composite Index

    7,266.69
    -7,317.24 (-50.17%)
     
  • PSE Index

    6,682.78
    +64.09 (+0.97%)
     

Senseonics Holdings, Inc. Schedules First Quarter 2024 Earnings Release and Conference Call for May 13, 2024 at 4:30 P.M. Eastern Time

GERMANTOWN, Md., April 30, 2024--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its first quarter 2024 financial results after market close on Monday, May 13, 2024.

Management will hold a conference call to review the Company’s first quarter 2024 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by navigating to "Investor Relations," and then "Events & Publications," and will be archived there for future reference. To listen to the conference call, please dial 1-888-317-6003 (US/Canada) or 1-412-317-6061 (International), passcode 7182212, approximately ten to five minutes prior to start time.

About Senseonics

Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics’ CGM system Eversense® E3 includes a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user’s smartphone.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240430201291/en/

Contacts

Investor Contact
Philip Taylor
Gilmartin Group
415-937-5406
Investors@senseonics.com